HC Wainwright Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

HC Wainwright reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $200.00 price target on the specialty pharmaceutical company's stock.

A number of other brokerages also recently commented on JAZZ. Cantor Fitzgerald restated an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, August 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. Piper Sandler reissued an "overweight" rating and issued a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $175.33.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded up $1.57 during mid-day trading on Friday, reaching $126.67. The stock had a trading volume of 885,835 shares, compared to its average volume of 679,381. The firm has a 50 day moving average price of $113.29 and a two-hundred day moving average price of $110.62. The stock has a market capitalization of $7.66 billion, a P/E ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 over the last quarter. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in JAZZ. Advisors Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 9.2% during the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company's stock valued at $1,171,000 after buying an additional 819 shares in the last quarter. Estuary Capital Management LP boosted its holdings in shares of Jazz Pharmaceuticals by 67.2% in the 1st quarter. Estuary Capital Management LP now owns 213,450 shares of the specialty pharmaceutical company's stock worth $25,704,000 after purchasing an additional 85,779 shares during the period. Sugar Maple Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $301,000. California State Teachers Retirement System boosted its holdings in shares of Jazz Pharmaceuticals by 3.2% in the 1st quarter. California State Teachers Retirement System now owns 102,353 shares of the specialty pharmaceutical company's stock worth $12,325,000 after purchasing an additional 3,172 shares during the period. Finally, Tidal Investments LLC boosted its holdings in shares of Jazz Pharmaceuticals by 179.4% in the 1st quarter. Tidal Investments LLC now owns 16,655 shares of the specialty pharmaceutical company's stock worth $2,006,000 after purchasing an additional 10,693 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.